BioSpace News Archive

Annexin Pharmaceuticals AB announces that an independent evaluation of potential signals of effect has been carried out in the company’s Phase 2-study in retinal vein occlusion with the investigational new drug ANXV.

Plus Therapeutics, Inc. reported positive data from the ReSPECT-LM clinical study evaluating the Company’s lead radiotherapeutic, rhenium obisbemeda, for the treatment of leptomeningeal metastases at the Society for Neuro Oncology /American Society of Clinical Oncology Central Nervous System Cancer Conference taking place August 10-12, 2023 in San Francisco, California.

Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”) announced today the Phase 2 ELPIS II trial, funded by the National Heart, Lung, and Blood Institute (NHLBI) and using the Company’s Lomecel-B™ asset in Hypoplastic Left Heart Syndrome (HLHS), has surpassed the 50% enrollment threshold.

Asieris Pharmaceuticals, a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that the Phase III bridging clinical trial of Hexvix® for bladder cancer diagnosis met the primary endpoint.

Akero Therapeutics, Inc., a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, reported second quarter financial results for the period ending June 30, 2023 and provided business updates.

HCW Biologics Inc. reported financial results and recent business highlights for its second quarter ended June 30, 2023.

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, today reported its financial results for the quarter ended June 30, 2023.

Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, announced its financial and operational results for the first quarter of its fiscal year 2024, which ended on June 30, 2023.

Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today reported financial results for the quarter ended June 30, 2023, and provided a corporate update.

CASI Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, reported financial results for the quarter ended June 30, 2023.